SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors gear up for the company's first earnings report since its public listing, with the community closely watching for updates on revenue scaling and the impact of recent government and defense contract wins. Market participants are actively debating the stock's long-term potential as a quantum sector leader, weighing its institutional backing and technological differentiation against short-term price volatility.

TOSHI

TOSHI is trending as investors aggressively accumulate the coin in anticipation of a potential market reversal and future catalysts, while the community remains divided between long-term confidence in the Base chain's "blue cat" and frustration over stagnant price action. Market participants are actively discussing strategic accumulation zones and comparing the coin's potential to other successful meme coin cycles.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense community scrutiny and negative sentiment following a sharp post-earnings selloff, with investors expressing deep frustration over management's performance and the disconnect between the company's financial guidance and its actual stock price. Despite some bulls pointing to long-term Disney synergy and a path to profitability, many market participants remain skeptical, citing a history of dilution and persistent subscriber losses as primary reasons for their lack of confidence.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer remains in the spotlight as investors debate the impact of ongoing management turnover and legal headwinds against the backdrop of massive global demand for AI infrastructure. The community is sharply divided, with some betting on a deep-value rebound supported by strong revenue growth and data center expansion, while others voice deep skepticism and frustration over the stock's volatility and the co-founder's recent legal troubles.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant investor interest as the community awaits further clinical data following its recent pancreatic cancer trial presentation at DDW 2026. Bulls are focusing on a series of upcoming catalysts, including the highly anticipated ASCO annual meeting and interim data from the REGAIN glioblastoma trial, as the company works toward broader scientific validation for its Alpha DaRT platform.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community debates its long-term potential as a leader in real-world asset (RWA) tokenization, with investors weighing institutional partnerships against concerns over upcoming token unlocks and price volatility. While some see the platform's ability to bridge traditional finance with blockchain as a major catalyst for future growth, others remain skeptical, focusing on short-term price stagnation and broader market uncertainty.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is seeing significant attention as investors monitor its deep integration into the AI infrastructure supply chain and hyperscaler spending trends. The community is actively debating the company's role in custom silicon and data center networking, weighing the potential impact of financing hurdles and broader sector volatility against its position as a primary beneficiary of massive AI capital expenditure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing intense volatility as retail investors debate whether the high-growth AI chipmaker is a legitimate threat to Nvidia or merely an overhyped IPO liquidity trap. Community members are aggressively trading the stock, with bullish participants citing the company's unique wafer-scale technology and massive backlogs, while skeptical voices warn that current valuations are detached from fundamentals and likely to face significant downward pressure following the initial frenzy.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is facing significant investor frustration as shares react negatively to conservative Q2 guidance and concerns over stalled user growth, despite the company delivering a quarterly earnings beat and continuing its aggressive share repurchase program. The community is deeply divided, with some investors highlighting the stock's low valuation and massive cash reserves as a potential value opportunity, while others remain skeptical of management's turnaround strategy and the persistent competitive pressure from big tech.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant volatility and trading near multi-year lows, fueling intense community debate between those viewing the price drop as a value-based buying opportunity and those concerned about the company's recent strategic acquisitions and litigation pressures. While some investors are actively accumulating shares based on historical valuation and long-term potential, others are increasingly frustrated by the persistent downward trend and lack of immediate institutional support.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Key PointsCMO David Raben sold 5,500 shares of common stock for a transaction value of $126,000 on April 27...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) insider David Raben sold 5,500 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of...

Ivan Hyep Sells 9,200 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 15,000 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction on Monday, April 20th. The stock was sold at an average price...

Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction dated Monday, April 20th. The shares were sold at an average...

Ryan Cohlhepp Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the business's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total value of $287,625.00. Following the sale, the chief operating officer...

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twelve brokerages that are currently covering the stock, Marketbeat reports...

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Current Price	$19.29
Prev Close	$20.23
Open	$20.92
Dividend Yield	0.00%
50-Day Moving Average	$21.12
Beta	1.71
Avg. Volume	526,295.58
PE Ratio	-6.96

52-Week High	$24.25
52-Week Low	$7.80
Market Capitalization	$1.33B
EPS (Annual)	-$2.52
Price to Book	2.46
Revenue Per Employee	$0.00

BCAX
Bicara Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAX News

BCAXBicara Therapeutics